Abstract | BACKGROUND: METHODS AND RESULTS: In the Justfication for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial (NCT00239681), participants with low-density lipoprotein cholesterol <130 mg/dL and high-sensitivity C-reactive protein ( hsCRP) ≥2 mg/L were randomized to rosuvastatin 20 mg/day or placebo. GlycA was quantified by nuclear magnetic resonance spectroscopy in 12 527 before randomization and 10 039 participants at 1 year. A total of 310 first primary CVD events occurred during maximum follow-up of 5.0 years (median, 1.9). GlycA changed minimally after 1 year on study treatment: 6.8% and 4.7% decrease in the rosuvastatin and placebo groups, respectively. Overall, baseline GlycA levels were associated with increased risk of CVD: multivariable-adjusted hazard ratio (HR) per SD increment, 1.20 (95% CI, 1.08-1.34; P=0.0006). After additionally adjusting for hsCRP, this was slightly attenuated (HR, 1.18; 95% CI, 1.04-1.35; P=0.01). On-treatment GlycA levels were also associated with CVD; corresponding multivariable-adjusted HRs per SD before and after additionally adjusting for hsCRP: 1.27 (95% CI, 1.13-1.42; P<0.0001) and 1.24 (95% CI, 1.07-1.44; P=0.004), respectively. Tests for heterogeneity by treatment arm were not significant (P for interaction, >0.20). CONCLUSION: In the JUPITER trial, increased levels of GlycA were associated with an increased risk of CVD events independent of traditional risk factors and hsCRP. CLINICAL TRIALS REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00239681.
|
Authors | Akintunde O Akinkuolie, Robert J Glynn, Latha Padmanabhan, Paul M Ridker, Samia Mora |
Journal | Journal of the American Heart Association
(J Am Heart Assoc)
Vol. 5
Issue 7
(07 13 2016)
ISSN: 2047-9980 [Electronic] England |
PMID | 27413042
(Publication Type: Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural)
|
Copyright | © 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell. |
Chemical References |
- Anticholesteremic Agents
- Biomarkers
- Rosuvastatin Calcium
- C-Reactive Protein
- Acetylglucosamine
|
Topics |
- Acetylglucosamine
(blood)
- Aged
- Anticholesteremic Agents
(therapeutic use)
- Biomarkers
(blood)
- C-Reactive Protein
(analysis)
- Cardiovascular Diseases
(blood, diagnosis, prevention & control)
- Double-Blind Method
- Female
- Humans
- Male
- Middle Aged
- Risk
- Rosuvastatin Calcium
(therapeutic use)
|